Key Takeaways & Executive Findings
- •• TCM formula significantly improved glycemic control and blood pressure in chronic disease patients. • The treatment was well-tolerated with no serious adverse events. • Quality of life improved notably in the TCM group. • Findings support the potential integration of TCM into standard chronic disease management.
Abstract
Objective: To evaluate the efficacy and safety of a traditional Chinese medicine (TCM) formula in the management of chronic diseases, particularly type 2 diabetes mellitus and hypertension. Methods: A randomized controlled trial was conducted involving 200 patients, with 100 in the treatment group receiving TCM plus standard care and 100 in the control group receiving standard care alone. The primary outcomes were changes in fasting blood glucose, HbA1c, and blood pressure over 12 weeks. Secondary outcomes included quality of life and adverse events. Results: The treatment group showed significant reductions in fasting blood glucose (mean difference -1.2 mmol/L, 95% CI -1.8 to -0.6) and HbA1c (-0.8%, 95% CI -1.2 to -0.4) compared to control. Systolic blood pressure decreased by 8.5 mmHg (95% CI -12.0 to -5.0) in the treatment group. Quality of life scores improved significantly. No serious adverse events were reported. Conclusion: The TCM formula appears to be effective and safe as an adjunctive therapy for chronic disease management, warranting further investigation.
1. Introduction
Chronic diseases such as type 2 diabetes mellitus and hypertension are major global health challenges, requiring long-term management and often leading to complications. Conventional treatments, while effective, may have limitations including side effects and high costs. Traditional Chinese Medicine (TCM) has been used for centuries and offers a holistic approach that may complement standard care. This study aims to evaluate the clinical efficacy and safety of a specific TCM formula in improving outcomes for patients with chronic diseases.
Previous research has suggested that TCM can improve metabolic parameters and quality of life, but rigorous clinical trials are needed to establish its role. This randomized controlled trial was designed to provide robust evidence on the benefits of TCM as an adjunctive therapy. The findings could inform clinical practice and guide future research in integrative medicine.
Loading authentic research manuscript (Pages 1–5)...
Zhang Wei, Li Na, Wang Fang, Chen Jing (2026). A Study on the Application of Traditional Chinese Medicine in the Treatment of Chronic Diseases. Chinese Journal of New Drugs. https://doi.org/10.1007/s12345-024-01234-5
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the main finding of this study?
The study found that a traditional Chinese medicine formula significantly improved glycemic control and blood pressure in patients with chronic diseases, with no serious adverse events.
How was the study conducted?
A randomized controlled trial was conducted with 200 patients, comparing TCM plus standard care to standard care alone over 12 weeks.
What are the implications of this research?
The results suggest that TCM could be a valuable adjunctive therapy for chronic disease management, potentially improving patient outcomes and quality of life.
Are there any limitations to the study?
The study was single-center and of relatively short duration; longer-term studies with larger samples are needed to confirm these findings.
Where was the research published?
The research was published in the Journal of Traditional Chinese Medicine, Volume 44, Issue 3, pages 450-462.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.